(Q45884850)

17 December 2017

title

An effective immunization and cancer treatment with activated dendritic cells transduced with full-length wild-type p53. (English)

1 reference

17 December 2017

0 references

1 reference

Nikitina EY

1

1 reference

17 December 2017

Chada S

2

1 reference

17 December 2017

Muro-Cacho C

3

1 reference

17 December 2017

Fang B

4

1 reference

17 December 2017

Zhang R

5

1 reference

17 December 2017

Roth JA

6

1 reference

17 December 2017

Gabrilovich DI

7

1 reference

17 December 2017

publication date

1 March 2002

1 reference

17 December 2017

published in

Gene Therapy

1 reference

17 December 2017

volume

9

1 reference

17 December 2017

issue

5

1 reference

17 December 2017

page(s)

345-352

1 reference

17 December 2017

DNA damage induces phosphorylation of the amino terminus of p53

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301670

WAF1, a potential mediator of p53 tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301670

Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301670

14-3-3sigma is a p53-regulated inhibitor of G2/M progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301670

A novel form of Epstein-Barr virus latency in normal B cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301670

A model for p53-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301670

p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301670

The emerging p53 gene family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301670

The p53 tumour suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301670

Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301670

Targeting p53 as a general tumor antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301670

Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301670

Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301670

p53, a potential target for tumor-directed T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301670

Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301670

Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301670

Dendritic cells: development, function and potential use for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301670

Dendritic cell vaccines for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301670

Effective repeat administration with adenovirus vectors to the muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301670

Evidence that HLA class II-restricted human CD4+ T cells specific to p53 self peptides respond to p53 proteins of both wild and mutant forms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301670

Dendritic cell activation induced by various stimuli, e.g. exposure to microorganisms, their products, cytokines, and simple chemicals as well as adhesion to extracellular matrix

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301670

Dendritic cells: expansion and differentiation with hematopoietic growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301670

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301670

Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301670

IL-12 and mutant P53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301670

7 January 2021

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301670

7 January 2021

Characterization of CD8+ cytotoxic T lymphocyte/tumor cell interactions reflecting recognition of an endogenously expressed murine wild-type p53 determinant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301670

7 January 2021

Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301670

7 January 2021

Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301670

7 January 2021

Identifiers

DOI

10.1038/SJ.GT.3301670

1 reference

17 December 2017

Dimensions Publication ID

1029618834

0 references

1 reference

17 December 2017